Bexorg, which describes itself as “a pioneering techbio company working to decode the human brain and advance new therapies for central nervous system disorders,” announced a multi-program research collaboration with Biohaven (BHVN) to identify, de-risk, and advance next-generation therapies for CNS disorders. “As part of the collaboration, Bexorg’s novel whole-brain discovery platform will be used to demonstrate target engagement in relevant cell types and tissues and generate novel biomarkers, pharmacokinetic and pharmacodynamic relationships, and other mechanistic data to support two preclinical development programs at Biohaven,” the company stated. “As part of the collaboration, Bexorg aims to deliver insights from systemic delivery of Biohaven’s therapeutics, including analysis of pharmacokinetics, pharmacodynamics, and mechanism of action. Data generated from the platform may also potentially point to the responsiveness of patient subpopulations and identify novel biomarkers to inform clinical trials. Financial terms of the collaboration were not disclosed,” the company added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Biohaven Ltd. Highlights Strategic Focus in Investor Presentation
- 3 Best Stocks to Buy Now, 6/2/2025, According to Top Analysts
- 3 Best Stocks to Buy Now, 5/30/2025, According to Top Analysts
- Biohaven Ltd. Receives Buy Rating from Douglas Tsao Amid Promising R&D Advancements and Strategic Developments
- Biohaven Ltd. Receives Buy Rating Amidst Promising Developments and Strategic Advancements
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue